Last reviewed · How we verify
NCT06889493
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Phase 1 trial testing Seneca Valley Virus-001 (SVV-001) in Neuroendocrine Carcinoma in 36 participants. Currently enrolling.
1 June 2030
Quick facts
| Lead sponsor | Peter Hosein, MD |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 19 May 2025 |
| Primary completion | 1 June 2030 |
| Estimated completion | 1 June 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Seneca Valley Virus-001 (SVV-001) — full drug profile →
- Nivolumab (nivolumab) — full drug profile →
- Ipilimumab — full drug profile →
Conditions studied
- Neuroendocrine Carcinoma — all drugs for Neuroendocrine Carcinoma →
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Sponsor
Peter Hosein, MD — full company profile →
Who can join
18 and older, any sex, with Neuroendocrine Carcinoma or Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer.
Jin S, Zhang Y, Zhou Z, Zhang Y, et al · · 2026 · PMID 41970230 · DOI 10.1002/mco2.70725 -
New Treatment Options for Pancreatic Neuroendocrine Tumors: A Narrative Review.
Romanowicz A, Fudalej M, Asendrych-Woźniak A, Badowska-Kozakiewicz A, et al · · 2025 · PMID 41375037 · DOI 10.3390/cancers17233837
Verify or expand the search:
- PubMed search for NCT06889493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuroendocrine Carcinoma
Currently open trials in the same condition.
- NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting
- NCT06577987 — Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies · Phase 1 · recruiting
- NCT06242119 — Clinical Application of the J-PET Scanner Prototype · recruiting
- NCT04524208 — A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 · Phase 2 · active not recruiting
- NCT04701307 — Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas · Phase 2 · active not recruiting
Other Peter Hosein, MD trials
Trials by the same sponsor.
- NCT05440942 — Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06889493 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peter Hosein, MD
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06889493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing